AE	Adverse event
AKI	Acute kidney injury
AML	Acute myeloid leukemia
AZA	Azacitidine
CART	Classification and regression trees
CHIP	Clonal hematopoiesis of indeterminate potential
CI	Confidence interval
CKD	Chronic kidney disease
CR	Complete remission
CRi	Complete remission with incomplete blood count recovery
CTCE	Common Terminology Criteria for Adverse Events
CTLS	Clinical tumor lysis syndrome
ECOG	Eastern Cooperative Oncology Group
EFS	Event-free survival
eGFR	Estimated glomerular filtration rate
ELN	European LeukemiaNet
HMA	Hypomethylating agents
HR	Hazard ratio
ICC	International consensus classification
KDIGO	Kidney disease improving global outcomes
KT	karyotype
LDAC	Low-dose cytarabine
LTLS	Laboratory tumor lysis syndrome
MPN	Myeloproliferative neoplasms
mPRS	Molecular prognostic risk signature
MRCA	Myelodysplasia-related cytogenetic abnoramlities
MRGM	Myelodysplasia-related gene mutations
mut	mutated
MVA	Multivariable analysis
OR	Odds ratio
ORR	Overall response rate
OS	Overall survival
p	p-value
PK	pharmacokinetics
RFS	Relapse-free survival
TLS	Tumor lysis syndrome
UVA	Univariate analysis
VEN	Venetoclax
VENreg	Venetoclax registry
WBC	White blood cell
wt	Wildtype